The Haematology Research Group (HemRG) at La Fe University Hospital is a consolidated research group in our institution and is constituted by researchers with extensive experience and prestige (both on national and international level) in hematological neoplasms, mainly of myeloid lineage. Our Group aims to contribute to a better understanding of hematological malignancies (cytomorphology, pathology, molecular genetics and potential therapeutic targets), as well as, to establish new standards of clinical care. The group consists of both, researchers and clinicians, with expertise in a broad number of disciplines. This grants the group a markedly multidisciplinary character, essential for the development of clinical and preclinical therapeutic models. The majority of these researchers have well-established collaborations with the pharmaceutical industry with a track record to deliver results in research projects, clinical trials or acting as reference laboratories. This combination of national and international clinical recognition, solid track-record in delivering high quality science and long-established collaborations with the pharmaceutical industry, creates an exceptional medium in the path towards personalized care. The composition of the group also aims to find a balance in the presence of senior and young researchers.
Several ongoing national and international projects (such as, 16/011113, 16/00665,18/01340, 18/01472, 18/00280, TRANSCAN-2 2015/0335, HARMONY IMI2-2015, MDS-RIGHT 2015 and PROMETEOII/2015/008) and numerous cooperative scientific publications support the ability of our group to collaborate with other partners, such as the Italian Cooperative Group for the Study of Malignant Hematological Diseases of the Adult (GIMEMA), the German-Austrian AML Study Group (AMLSG), European LeukemiaNet, PETHEMA, CETLAM, GETH, SEHOP and GESMD, among others.
The PI of the group, Prof. Miguel Sanz, during the past three decades, has mainly focused on clinical and biological characterization of acute leukemia (AML) and myelodysplastic syndromes (MDS), as well as on chemotherapy, stem cell transplantation, and supportive therapy for malignant hematological diseases. He has developed a remarkable scientific activity regarding various aspects of the characterization and treatment of myeloid malignancies, been particularly notable his contributions in the field of acute promyelocytic leukemia (APL). Prof. Miguel Sanz is chairman of the Spanish PETHEMA Group, leading the APL and AML Working Parties. The impact of the clinical trials carried out on APL by this group are perceived not only by the many reports published in top journals (Blood, J Clin Oncol, Leukemia, among others) but the adoption of the so-called “Spanish (PETHEMA) approach” as a standard regimen for APL in several European countries (UK, The Netherlands, Italy, Germany, Poland, etc.). Besides, Prof. Miguel Sanz is co-leader of the AML Work package of the European LeukemiaNet (http://www.leukemia-net.org/) and chairman of the protocol for APL of the International Consortium of APL (http://www.Haematology.org/Global/206.aspx). This is an innovative project of the American Society of Haematology to promote cooperation between Western expert groups in the field of APL and developing countries, as well as developing an international network on the study of APL. Well-known APL experts from the US, Europe, South and Central America, Middle East, and Asia have been involved in this unprecedented endeavor. Among the many scientific contributions made by Prof. Miguel Sanz, the scoring system for predicting the risk of relapse is particularly noteworthy, which is now used all over the world to design risk-adapted strategies in APL. In fact, the strategy and treatment proposed by the PETHEMA group (Spanish approach) are considered the gold standard for the management of patients with this disease.